872882-97-8

Basic information

• Product Name: 3-(4-Bromophenyl)-3-methyloxetane
• Synonyms: 3-(4-Bromophenyl)-3-methyloxetane
• CAS NO: 872882-97-8
• Molecular Formula: C₁₀H₁₁BrO
• Molecular Weight: 227.09774
• Mol File: 872882-97-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-Bromophenyl)-3-methyloxetane(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Bromophenyl)-3-methyloxetane(872882-97-8)
• EPA Substance Registry System: 3-(4-Bromophenyl)-3-methyloxetane(872882-97-8)

Safety Data

• Hazardous Substances Data: 872882-97-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Bromophenyl)-3-methyloxetane is used as a building block in organic synthesis for the development of pharmaceuticals. Its unique structure and reactivity contribute to the creation of complex organic molecules, which are essential in designing and producing new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(4-Bromophenyl)-3-methyloxetane serves as a key component in the synthesis of various agrochemicals. Its role in building complex molecules aids in the development of effective products for agricultural applications.
Used in Research and Development Laboratories:
3-(4-Bromophenyl)-3-methyloxetane is utilized as a reagent in research and development laboratories. It plays a crucial role in the synthesis of a wide range of substances, supporting scientific advancements and innovation in organic chemistry.
Overall, 3-(4-Bromophenyl)-3-methyloxetane holds an essential position in the field of organic chemistry, with its diverse applications spanning across multiple industries, including pharmaceuticals, agrochemicals, and research and development.

Upstream product

• 99-90-1 para-bromoacetophenone 
• 80909-78-0 p-bromo-α-methylstyrene oxide 
• 10242-62-3 3-methyleneoxetane 
• 106-37-6 1.4-dibromobenzene 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 
• 93139-85-6 2-(4-bromophenyl)malonic acid diethyl ester 
• 872882-98-9 diethyl 2-(4-bromophenyl)-2-methylmalonate 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 66810-01-3 2-(4-bromophenyl)-2-methylpropane-1,3-diol 
• 603-35-0 triphenylphosphine 
• 53578-00-0 2-(4-Bromophenyl)-2,2-dimethoxyethane 

Downstream Products

• 1431616-23-7 6-(4-(3-methyloxetan-3-yl)phenyl)nicotinonitrile 
• 1315567-78-2 4-(3-methyloxetan-3-yl)benzoic acid 
• 1431616-42-0 (4-(3-methyloxetan-3-yl)phenyl)boronic acid 
• 1262049-69-3 (5R,8S,11R,13S,14S,17S)-5',5',13-trimethyl-11-[4-(3-methyloxetan-3-yl)phenyl]-17-(pentafluoroethyl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxane]-5,17(4H)-diol 

Relevant articles and documents

Chemical space exploration of oxetanes

This paper focuses on new derivatives bearing an oxetane group to extend accessible chemical space for further identification of kinase inhibitors. The ability to modulate kinase activity represents an important therapeutic strategy for the treatment of h

Quaternary Centers by Nickel-Catalyzed Cross-Coupling of Tertiary Carboxylic Acids and (Hetero)Aryl Zinc Reagents

This work bridges a gap in the cross-coupling of aliphatic redox-active esters with aryl zinc reagents. Previously limited to primary, secondary, and specialized tertiary centers, a new protocol has been devised to enable the coupling of general tertiary systems using nickel catalysis. The scope of this operationally simple method is broad, and it can be used to simplify the synthesis of medicinally relevant motifs bearing quaternary centers.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Iron-Nickel Dual-Catalysis: A New Engine for Olefin Functionalization and the Formation of Quaternary Centers

Alkene hydroarylation forms carbon-carbon bonds between two foundational building blocks of organic chemistry: olefins and aromatic rings. In the absence of electronic bias or directing groups, only the Friedel-Crafts reaction allows arenes to engage alkenes with Markovnikov selectivity to generate quaternary carbons. However, the intermediacy of carbocations precludes the use of electron-deficient arenes, including Lewis basic heterocycles. Here we report a highly Markovnikov-selective, dual-catalytic olefin hydroarylation that tolerates arenes and heteroarenes of any electronic character. Hydrogen atom transfer controls the formation of branched products and arene halogenation specifies attachment points on the aromatic ring. Mono-, di-, tri-, and tetra-substituted alkenes yield Markovnikov products including quaternary carbons within nonstrained rings.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.

SUBSTITUTED BIPIPERIDINYL DERIVATIVES

The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Metabolically stable tert-butyl replacement

Susceptibility to metabolism is a common issue with the tert-butyl group on compounds of medicinal interest. We demonstrate an approach of removing all the fully sp3 C-Hs from a tert-butyl group: replacing some C-Hs with C-Fs and increasing the s-character of the remaining C-Hs. This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability. Trifluoromethylcyclopropyl-containing analogues had consistently higher metabolic stability in vitro and in vivo compared to their tert-butyl-containing counterparts.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.